[HTML][HTML] Artificial intelligence in COVID-19 drug repurposing
Drug repurposing or repositioning is a technique whereby existing drugs are used to treat
emerging and challenging diseases, including COVID-19. Drug repurposing has become a …
emerging and challenging diseases, including COVID-19. Drug repurposing has become a …
AlphaFold, artificial intelligence (AI), and allostery
R Nussinov, M Zhang, Y Liu, H Jang - The Journal of Physical …, 2022 - ACS Publications
AlphaFold has burst into our lives. A powerful algorithm that underscores the strength of
biological sequence data and artificial intelligence (AI). AlphaFold has appended projects …
biological sequence data and artificial intelligence (AI). AlphaFold has appended projects …
Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's …
We developed an endophenotype disease module-based methodology for Alzheimer's
disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier …
disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier …
[HTML][HTML] Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment
Background Dementia-like cognitive impairment is an increasingly reported complication of
SARS-CoV-2 infection. However, the underlying mechanisms responsible for this …
SARS-CoV-2 infection. However, the underlying mechanisms responsible for this …
[HTML][HTML] Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease
Translating human genetic findings (genome-wide association studies [GWAS]) to
pathobiology and therapeutic discovery remains a major challenge for Alzheimer's disease …
pathobiology and therapeutic discovery remains a major challenge for Alzheimer's disease …
[HTML][HTML] The promise of microRNA-based therapies in Alzheimer's disease: challenges and perspectives
H Walgrave, L Zhou, B De Strooper, E Salta - Molecular …, 2021 - Springer
Multi-pathway approaches for the treatment of complex polygenic disorders are emerging as
alternatives to classical monotarget therapies and microRNAs are of particular interest in …
alternatives to classical monotarget therapies and microRNAs are of particular interest in …
Association predictions of genomics, proteinomics, transcriptomics, microbiome, metabolomics, pathomics, radiomics, drug, symptoms, environment factor, and …
Currently, the research of multi‐omics, such as genomics, proteinomics, transcriptomics,
microbiome, metabolomics, pathomics, and radiomics, are hot spots. The relationship …
microbiome, metabolomics, pathomics, and radiomics, are hot spots. The relationship …
Applied machine learning in Alzheimer's disease research: omics, imaging, and clinical data
Alzheimer's disease (AD) remains a devastating neurodegenerative disease with few
preventive or curative treatments available. Modern technology developments of high …
preventive or curative treatments available. Modern technology developments of high …
Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications …
Because disease-associated microglia (DAM) and disease-associated astrocytes (DAA) are
involved in the pathophysiology of Alzheimer's disease (AD), we systematically identified …
involved in the pathophysiology of Alzheimer's disease (AD), we systematically identified …
[HTML][HTML] Artificial intelligence for drug discovery and development in Alzheimer's disease
The complex molecular mechanism and pathophysiology of Alzheimer's disease (AD) limits
the development of effective therapeutics or prevention strategies. Artificial Intelligence (AI) …
the development of effective therapeutics or prevention strategies. Artificial Intelligence (AI) …